Virocell Biologics

Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients. We develop next-generation therapeutics using our proprietary platform that delivers the right gene to the right place at the right time with unparalleled precision and versatility. Lorenz Mayr, Ph.D. is the Chief Executive Officer and co-founder of Vector BioPharma. Sheena Smith, Ph.D., is the Head of Program Management at Vector BioPharma. She is a protein engineer with expert knowledge of gene and cell therapy, biochemical immunology, and directed evolution.

We are a company driven by immunology in the pursuit of powerful prevention and treatment of disease. Our vision is to stimulate and amplify the human immune system to target and overcome significant infectious diseases and aggressive cancers. VBI is a global biopharmaceutical company, with corporate headquarters in Cambridge, MA, United States, research and development facilities in Ottawa, Canada, and a research and manufacturing facility in Rehovot, Israel. At VBI, we believe that it takes the power of many great minds and organizations to solve the toughest challenges. Patriarca, M.D., is the Principal of Immuno-Vax, LLC, and a senior affiliate consultant with the Biologics Consulting Group, Inc. Patriarca served, among other positions, as Director of the Division of Viral Products in the Office of Vaccines Research and Review (OVRR), CBER. De Wilde a member of a number of Scientific Advisory Boards, including COVAX Independent Product Group and other COVID related advisory bodies. Daniel Shouval is a graduate of the Hadassah–Hebrew University Medical School in Jerusalem, Israel.

Vir’s core capabilities include our deep immunology and virology expertise, our proven world-class monoclonal antibody platform with AI-led protein engineering capabilities, as well as our T cell-based viral vector platform. Vir has built a broad pipeline with several ongoing trials – including two late-stage programs in chronic hepatitis delta and chronic hepatitis B – that we believe will support near- and long-term growth, along with multiple potential INDs in the next 12-24 months. If you share our goal of addressing the unmet needs of patients around the world, please visit our careers page for open positions. Our growth and pursuit of scientific innovation is fueled by our leading monoclonal antibody (mAb) platform that has a proven track record and is further strengthened by our artificial intelligence-led mAb optimization and engineering capabilities. Our ability to develop impactful medicines for major public health challenges is a testament to the company’s deep knowledge of immunology and our ability to understand the interplay between viruses and the human immune system.”. We have an industry-leading management team and Board of Directors with significant immunology and infectious diseases experience, including a proven track record of progressing product candidates from early-stage research through clinical development, and worldwide regulatory approval and commercialization. We offer the opportunity to do challenging, rewarding work as part of our world class teams in the U.S.

Virovek specializes in large-scale and custom-made adeno-associated virus (AAV) vector production through our innovative and patented BAC-to-AAV and toxin-based cell ablation technologies. Since 2006, Virovek has produced thousands of AAV vectors at 1E+13vg scale or above to support research projects in over 100 university laboratories, non-profit institutions, and industry leaders worldwide. Virovek, a commercial-stage biotechnology company specializing in the development, manufacturing and sale of custom-made AAV- and lentivirus-based vectors for therapeutic development, today announced that the Company has appointed Peter L. Virovek is launching an online storefront for premade product sales. Virovek may keep samples and remainders of custom-made AAV for customers up to 4 years after your initial order. Virovek accepts purchase orders, credit cards, checks, and wire transfers. Virovek’s patented BAC-TO-AAV technology has the capability of generating over 1E+16vg of adeno-associated virus in a single run. Striving for excellence in gene delivery to support basic science research and the clinical-stage drug development of the future.

Mark Leuchtenberger, MBA, joined SpyBiotech as our Chief Executive Officer (CEO). SpyBiotech and Serum Institute of India announced the signing of an exclusive global licensing agreement for the development of a novel virus-like-particle (VLP) vaccine targeting COVID-19. SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses. SpyBiotech is a clinical stage company utilizing its unique protein superglue technology to develop vaccines against infectious disease and cancer. We are developing a novel vaccine against human cytomegalovirus (HCMV), a widespread disease with life-threatening implications, particularly for babies and children, that currently lacks effective treatment or prevention. The start of our story is a unique protein superglue. We have completed the GMP manufacturing of our HCMV candidate with clinical trials planned for 2023.

Sunil David founded ViroVax, LLC in 2019 in Lawrence, KS. ViroVax is a biotechnology company focused on research and development of vaccines, adjuvants, and therapeutics to protect and treat people from infectious diseases, including Zika, West Nile, Dengue, and SARS-CoV-2 .